Log in to search using one of your social media accounts:

 

Janssen Submits Supplemental New Drug Application to U.S. FDA for ZYTIGA ® (abiraterone acetate) to Treat Men with Earlier Stages of Metastatic Prostate Cancer
Filing Supported by Data from Pivotal LATITUDE Trial Evaluating ZYTIGA ® in Combination with Prednisone and Androgen Deprivation Therapy (ADT) (Source: Johnson and Johnson)
Source: Johnson and Johnson - September 14, 2017 Category: Pharmaceuticals Source Type: news

New Data Presented at ESMO 2017 Shows That Abiraterone Acetate Plus Prednisone Provides Benefits in Patient Reported Outcomes in Both Metastatic Hormone-Sensitive and Castration-Resistant Prostate Cancer
(Source: Johnson and Johnson)
Source: Johnson and Johnson - September 8, 2017 Category: Pharmaceuticals Source Type: news

New Data Change Metastatic Prostate Cancer Treatment Paradigm New Data Change Metastatic Prostate Cancer Treatment Paradigm
Dr Chodak reviews results of the LATITUDE trial, which compared ADT alone versus ADT with abiraterone acetate plus prednisone.Medscape Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 14, 2017 Category: Consumer Health News Tags: Urology Commentary Source Type: news

Churchill Pharmaceuticals Announces NDA Filing Acceptance for YONSA(TM) by the U.S. FDA
The NDA contains data to support approval for YONSA, (abiraterone acetate) ultramicrosize tablets, for the treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Churchill Pharmaceuticals also announces positive results from the pivotal ST... Biopharmaceuticals, Oncology, FDA Churchill Pharmaceuticals, YONSA, abiraterone, Prostate Cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 20, 2017 Category: Pharmaceuticals Source Type: news

Drugs Score Big Wins Against Lung, Prostate, Breast Cancers
CHICAGO (AP) — Drugs are scoring big wins against common cancers, setting new standards for how to treat many prostate, breast and lung tumors. There’s even a “uni-drug” that may fight many forms of the disease. What’s striking: The drugs are beneficial in some cases for more than a year, much longer than the few months many new drugs provide. Here are highlights from the world’s largest cancer meeting, the American Society of Clinical Oncology conference in Chicago. PROSTATE CANCER Janssen Biotech’s Zytiga improved survival and delayed cancer growth for 18 months when added to sta...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - June 5, 2017 Category: Consumer Health News Authors: Health – CBS Boston Tags: Breast Cancer Health News Prostate Cancer Source Type: news

Early use of J & J's Zytiga extends prostate cancer survival
CHICAGO (Reuters) - Adding Johnson& Johnson's Zytiga to standard hormone therapy reduced by nearly 40 percent the chance of death for men newly diagnosed with high-risk prostate cancer that had spread to other parts of the body, according to new trial results. (Source: Reuters: Health)
Source: Reuters: Health - June 3, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Abiraterone/ADT Combo Increased Prostate Cancer Survival
Combined therapy with abiraterone acetate/prednisone plus ADT significantly improved overall survival and radiographic progression-free survival among men with metastatic hormone-naive prostate cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASCO Prostate Cancer News Source Type: news

Drug Extends Lives of Patients With Advanced Prostate Cancer: Studies
SATURDAY, June 3, 2017 -- Men with advanced prostate cancer might be able to avoid chemotherapy by taking an additional anti-testosterone pill along with standard hormone therapy, a pair of new clinical trials show. The drug, abiraterone (Zytiga),... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 3, 2017 Category: General Medicine Source Type: news

Abiraterone Acetate Provided Significant Clinical Benefit in Patients with High-Risk Metastatic Hormone-Na ïve Prostate Cancer (mHNPC), Improving Overall Survival and Radiographic Progression-Free Survival
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 3, 2017 Category: Pharmaceuticals Source Type: news

Study shows early Zytiga use improves prostate cancer survival
CHICAGO (Reuters) - Adding Johnson& Johnson's Zytiga to standard hormone therapy reduced by nearly 40 percent the risk of death for men newly diagnosed with prostate cancer that had spread to other parts of the body, according to new trial results. (Source: Reuters: Health)
Source: Reuters: Health - June 3, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Churchill Pharmaceuticals Announces Submission of NDA for Yonsa (abiraterone acetate) Novel Oral Formulation of Prostate Cancer Treatment
King of Prussia, PA., May 23, 2017 Churchill Pharmaceuticals, LLC (Churchill) today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Yonsa (abiraterone acetate), an improved ultramicrosize... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - May 23, 2017 Category: Drugs & Pharmacology Source Type: news

ASCO 2017: Janssen to Present 19 Abstracts in Prostate Cancer and a Spectrum of Blood Cancers; Includes Data on Abiraterone Acetate, Daratumumab and Ibrutinib
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 18, 2017 Category: Pharmaceuticals Source Type: news

Trial: Abiraterone acetate responses even after initial hormone therapy failure
(University of Colorado Anschutz Medical Campus) Results of a 40-person clinical trial published in JAMA Oncology show that 13 percent of prostate cancer patients deemed 'hormone refractory' did, in fact, have strong responses to treatment with the next-generation hormonal drug abiraterone acetate. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 5, 2017 Category: Global & Universal Source Type: news

Low-Fat Meal May Boost Costly Cancer Drug
FRIDAY, Feb. 17, 2017 -- Eating a low-fat meal when taking an expensive prostate cancer drug can cut the cost of the drug by three-quarters, a new study indicates. " We know this drug [Zytiga] is absorbed much more efficiently when taken with food, " ... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 17, 2017 Category: Journals (General) Source Type: news

Zytiga (Abiraterone Acetate Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 31, 2016 Category: Drugs & Pharmacology Source Type: news

Abiraterone Acetate in Metastatic CRPCAbiraterone Acetate in Metastatic CRPC
Abiraterone acetate therapy for metastatic castration-resistant prostate cancer has shown efficacy in clinical trials, but are those same results achieved in real-world clinical practice? BMC Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 4, 2016 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Greater survival benefit shown in men with early and less aggressive mCRPC treated with Zytiga® plus prednisone
Janssen announced that data from a post-hoc analysis of the Phase III COU-AA-302 trial showed that ZYTIGA® plus prednisone provided an 11.8 months overall survival benefit, compared to an active control of placebo plus prednisone, in men with early and less aggressive chemotherapy-naïve metastatic castration-resistant prostate cancer (Source: Pharmacy Europe)
Source: Pharmacy Europe - March 14, 2016 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Oncology Patient care advanced prostate cancer COU-AA-302 trial European Association of Urology Latest News mCRPC Zytiga Source Type: news

Statins don’t appear to compromise effectiveness of abiraterone
SAN FRANCISCO – Statins do not reduce the effectiveness of abiraterone acetate in men with castration-resistant prostate cancer, and they may even prove to add to therapy, according to data reported... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - February 12, 2016 Category: Endocrinology Source Type: news

Statins don’t appear to compromise effectiveness of abiraterone
SAN FRANCISCO – Statins do not reduce the effectiveness of abiraterone acetate in men with castration-resistant prostate cancer, and they may even prove to add to therapy, according to data reported... (Source: Family Practice News)
Source: Family Practice News - February 12, 2016 Category: Primary Care Source Type: news

Study shows abiraterone acetate is useful even in most aggressive prostate cancers
(University of Colorado Anschutz Medical Campus) In study of nearly 2,000 prostate cancer patients, treatment with the androgen-lowering drug abiraterone acetate (Zytiga) led to longer overall disease control, even when a very high Gleason score indicated especially aggressive cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 3, 2015 Category: Global & Universal Source Type: news

Study Shows Abiraterone Acetate is Useful Even in Most Aggressive Prostate Cancers; University of Colorado Cancer Center
In 1,048 prostate cancer patients previously treated with docetaxel and 996 metastatic, castration-resistant patients, treatment with the androgen-lowering drug abiraterone acetate led to longer overall disease control, even when a very high Gleason score indicated especially aggressive cancer. Results recently published in the Annals of Oncology show that for patients with Gleason score greater than 8, post-docetaxel treatment with abiraterone extended progression-free survival from 5.5 months ... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - December 3, 2015 Category: Cancer & Oncology Source Type: news

Zytiga (abiraterone)—The Next Step after...
Zytiga is used after resistance to Lupron for prostate cancer. Men were shown to live 33% longer than those men who received a placebo. (Source: About.com Prostate Cancer)
Source: About.com Prostate Cancer - April 10, 2015 Category: Cancer & Oncology Tags: health Source Type: news

NICE rejects Zytiga as prostate cancer treatment before chemotherapy
In its final draft guidance, NICE has not recommended abiraterone for prostate cancer in people who received hormone therapy (androgen deprivation) but whose disease has spread, who have few symptoms and when chemotherapy would not yet have been given. (Source: Pharmacy Europe)
Source: Pharmacy Europe - August 15, 2014 Category: Drugs & Pharmacology Authors: ebercott Tags: *** Editor's Pick Oncology abiraterone janssen Latest News nice prostate cancer Zytiga Source Type: news

Prostate cancer patients 'unjustly' denied drug
A prostate cancer drug that can extend life by five years has been refused by the NHS drugs rationing body (Source: Telegraph Health)
Source: Telegraph Health - August 15, 2014 Category: Consumer Health News Tags: abiraterone Zytiga Nice Source Type: news

Rapid PSA Decline and Resistance to Abiraterone AcetateRapid PSA Decline and Resistance to Abiraterone Acetate
What are the factors predicting primary resistance to new-generation hormonal agents in patients with castration-resistant prostate cancer? Future Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 1, 2014 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

What’s New in the Treatment of Prostate...
Prostate Cancer Treatments: Treatment options for metastatic castration-resistant prostate cancer including Zytiga, Xtandi, Provenge & Xofigo (Source: About.com Prostate Cancer)
Source: About.com Prostate Cancer - May 27, 2014 Category: Cancer & Oncology Authors: prostatecancer.guide at about.com Tags: health Source Type: news

What’s New in the Treatment of Prostate...
Prostate Cancer Treatments: Treatment options for metastatic castration-resistant prostate cancer including Zytiga, Xtandi, Provenge & Xofigo (Source: About.com Prostate Cancer)
Source: About.com Prostate Cancer - May 1, 2014 Category: Cancer & Oncology Tags: health Source Type: news

Janssen's prostate cancer drug Zytiga now available in Trinidad and Tobago
The Chemistry, Food & Drugs Division of the Trinidad and Tobago Ministry of Health has approved Janssen's first orally administered androgen synthesis inhibitor (testosterone) medication 'Abiraterone Acetate' in the country for treatment of patients … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - April 15, 2014 Category: Pharmaceuticals Source Type: news

Bayer starts patient enrolment in Phase III prostate cancer trial
Bayer HealthCare has started patient enrolment in a new Phase III trial of radium-223 dichloride (radium-223, Xofigo) in combination with abiraterone acetate and prednisone/prednisolone to treat asymptomatic or mildly symptomatic chemotherapy-naïve p… (Source: Drug Development Technology)
Source: Drug Development Technology - April 4, 2014 Category: Pharmaceuticals Source Type: news

02.04.14: Not intended for U.S. and UK Media
Bayer Initiates Phase III Trial of Radium-223 Dichloride in Combination with Abiraterone Acetate for Patients with Metastatic Castration-Resistant Prostate Cancer mehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - April 2, 2014 Category: Pharmaceuticals Source Type: news

J&J Cancer Drug Zytiga Has New Competition
New study results for prostate cancer drug Xtandi showed that the drug prolonged lives and delayed tumor progression when used before chemotherapy. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - January 30, 2014 Category: Pharmaceuticals Source Type: news

AstraZeneca and Janssen to jointly promote prostate cancer treatment in Japan
UK-based drugmaker AstraZeneca and Janssen Pharmaceuticals K.K have entered into a co-promotion agreement for a new oral therapy called abiraterone acetate, a CYP17-inhibitor, to treat prostate cancer patients. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 14, 2013 Category: Pharmaceuticals Source Type: news

Evidence for Improved Patient Quality of Life With Prostate Cancer Drug
Abiraterone acetate in combination with prednisone delays pain progression as well as health-related quality of life compared with prednisone alone in prostate cancer patients, a new study shows. (Source: Cancer Network)
Source: Cancer Network - September 30, 2013 Category: Cancer & Oncology Source Type: news

Abiraterone acetate delays quality of life decline in men with metastatic prostate cancer
(University of North Carolina Health Care) Abiraterone acetate, a recently FDA-approved drug used to treat men with metastatic castration-resistant prostate cancer, significantly delays progression of pain and quality of life deterioration when taken in conjunction with prednisone. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 24, 2013 Category: Cancer & Oncology Source Type: news

Does Abiraterone Offer An Added Benefit Compared With The Present Standard Therapy For Metastatic Prostate Cancer?
Certain men with metastatic prostate cancer have advantages in comparison with watchful waiting Abiraterone acetate (abiraterone for short, trade name: Zytiga) has been approved in Germany since December 2012 for men with metastatic prostate cancer that is not responsive to hormone blockade, who only have mild symptoms or so far none at all, and in whom chemotherapy is not yet indicated... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 5, 2013 Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news

Zytiga (abiraterone acetate) - Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Developed by Coughar Biotechnology, abiraterone acetate (CB7630) was discovered by the UK Institute for Cancer Research. (Source: Drug Development Technology)
Source: Drug Development Technology - April 29, 2013 Category: Pharmaceuticals Source Type: news

Zytiga Prolongs Prostate Cancer Survival
ORLANDO (MedPage Today) -- Survival improved and disease progression slowed in men with metastatic castration-resistant prostate cancer treated in first line with abiraterone acetate (Zytiga). (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 17, 2013 Category: Hematology Source Type: news

Follow-up Data Show ZYTIGA? Plus Prednisone Continues to Delay Progression of Metastatic Castration-Resistant Prostate Cancer in Patients without Prior Chemotherapy(Feb 12, 2013)
Orlando, Fla., February 12, 2013 ? Janssen Research & Development, LLC [Janssen] announced today that updated results showing ZYTIGA? (abiraterone acetate) plus prednisone continued to provide statistically significant improvements in disease progression compared to placebo plus prednisone, and longer overall survival in men with metastatic castration-resistant prostate cancer..... (Source: Johnson and Johnson)
Source: Johnson and Johnson - February 12, 2013 Category: Pharmaceuticals Source Type: news

Follow-up Data Show ZYTIGA® Plus Prednisone Continues to Delay Progression of Metastatic Castration-Resistant Prostate Cancer in Patients without Prior Chemotherapy(Feb 12, 2013)
Orlando, Fla., February 12, 2013 – Janssen Research & Development, LLC [Janssen] announced today that updated results showing ZYTIGA® (abiraterone acetate) plus prednisone continued to provide statistically significant improvements in disease progression compared to placebo plus prednisone, and longer overall survival in men with metastatic castration-resistant prostate cancer..... (Source: Johnson and Johnson)
Source: Johnson and Johnson - February 12, 2013 Category: Pharmaceuticals Source Type: news

ZYTIGA® approved in the EU
Janssen-Cilag International NV (Janssen) has announced that the European Commission (EC) has approved an extension to the license of the oral, once-daily medication ZYTIGA® (abiraterone acetate). (Source: Pharmacy Europe)
Source: Pharmacy Europe - January 15, 2013 Category: Drugs & Pharmacology Source Type: news

European Commission clears extended licence to JanssenZytiga
Janssen-Cilag International NV (Janssen) has announced European Commission approval of an extended licence to the oral, once-daily medication Zytiga (abiraterone acetate). (Source: Drug Development Technology)
Source: Drug Development Technology - January 15, 2013 Category: Pharmaceuticals Source Type: news

Addition of abiraterone acetate to prednisone improved fatigue in patients with prostate cancer
Sternberg CN. Ann Oncol. 2012;doi:10.1093/annonc/mds585. (Source: HemOncToday.com)
Source: HemOncToday.com - January 3, 2013 Category: Cancer & Oncology Source Type: news